Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications.
The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | George Magrath |
Contact Details
Address: 37000 Grand River Avenue, Suite 120 Farmington Hills, Michigan 48335 United States | |
| Phone | 248 957 9024 |
| Website | opusgtx.com |
Stock Details
| Ticker Symbol | IRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001228627 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development and Secretary |
| Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance |
| Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Bindu Manne | Head of Market Development and Commercialization |
| Erik Sims | Director and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 7, 2025 | DFAN14A | Filing |
| Jan 24, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 424B5 | Filing |
| Jan 7, 2025 | 8-K/A | [Amend] Current report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |